HC Wainwright Reiterates “Buy” Rating for Ekso Bionics (NASDAQ:EKSO)

HC Wainwright reaffirmed their buy rating on shares of Ekso Bionics (NASDAQ:EKSO) in a research report released on Tuesday,Benzinga reports. They currently have a $9.00 price target on the stock. HC Wainwright also issued estimates for Ekso Bionics’ Q1 2025 earnings at ($0.11) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.25) EPS, FY2026 earnings at $0.00 EPS, FY2027 earnings at $0.12 EPS, FY2028 earnings at $0.27 EPS and FY2029 earnings at $0.46 EPS.

Separately, StockNews.com began coverage on Ekso Bionics in a research note on Monday. They issued a “hold” rating for the company.

Ekso Bionics Price Performance

Shares of NASDAQ EKSO opened at $0.40 on Tuesday. The firm has a market cap of $8.86 million, a P/E ratio of -0.62 and a beta of 1.46. The company has a quick ratio of 2.14, a current ratio of 2.81 and a debt-to-equity ratio of 0.28. The company has a 50 day moving average of $0.61 and a 200 day moving average of $0.82. Ekso Bionics has a twelve month low of $0.37 and a twelve month high of $1.64.

Ekso Bionics (NASDAQ:EKSO) last announced its earnings results on Monday, March 3rd. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.07). The company had revenue of $5.09 million for the quarter, compared to analysts’ expectations of $5.05 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. As a group, research analysts expect that Ekso Bionics will post -0.48 EPS for the current fiscal year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.